ClinicalTrials.gg
RecruitingNCT07622342Updated Oct 22, 2026

A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis

A Phase 2 interventional study of SHR-2173 injection and SHR-2173 injection in Generalized Myasthenia Gravis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 22, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 88 studies in Myasthenia Gravis with a site in China — 48 open to participants now, 60 under way, 17 of them phase 3. Myasthenia Gravis · China.

Planned enrollment
28th of 67
60 · median 40
Started
2026
with 17 others
Phase 2
5 of 88
2 open now
Primary completion
2027-09
later than 39 of 59 live
Registered
84th of 88
by date

Among the 88 studies in Myasthenia Gravis with a site in China, this one is the 28th largest by planned enrollment of the 67 interventional ones that give a count, is one of 18 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 39 of the 59 other live ones, and was the 84th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

48 of the 88 studies in Myasthenia Gravis with a site in China are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Myasthenia Gravis with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of SHR-2173 compared to placebo as an add-on therapy to standard of care (SOC) for the treatment of generalized myasthenia gravis (gMG). The study consists of a 4-week screening period, a 24-week treatment period, and a 12-week safety follow-up period.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants aged 18-75 years, confirmed diagnosis of generalized myasthenia gravis (gMG) (Myasthenia Gravis Foundation of America [MGFA] class II-IV).
  2. Positive for anti-AChR antibody or anti-MuSK antibody.
  3. MG-ADL total score ≥5 at screening and baseline, with >50% of the score attributable to non-ocular items.
  4. QMG score ≥11 at screening and baseline.
  5. Maintenance on stable standard of care (SOC) therapy.
  6. No to at least one rescue therapy: IVIg or PLEX.
  7. Provided written (ICF) after full understanding of the study content, procedures, and potential adverse reactions.
  8. Female subjects with fertility or male participants whose partners are women of childbearing age must avoid donating sperm/eggs from the date of signing the ICF until 12 weeks after the last study medication, and agree to take measures as specified in the protocol

Exclusion criteria

Exclusion Criteria:

  1. Presence of any of the following medical histories or comorbidities:

    1. Any untreated thymic epithelial tumor, mediastinal germ cell tumor, or other malignant mediastinal mass; or any thymic cyst or other mass requiring immediate intervention per investigator judgment;
    2. Previous history of thymic tumor not meeting protocol requirements;
    3. Myasthenic crisis (MGFA Class V) within 3 months prior to randomization;
    4. Any known disease other than gMG that may interfere with study procedures and assessments;
    5. A history of progressive multifocal leukoencephalopathy (PML);
    6. A history of body irradiation or organ transplantation.
  2. Use of any of the following drugs/treatments or participation in a clinical study:

    1. Prior treatment with CAR-T or other cellular therapy, or T-cell engager (TCE) therapy;
    2. Anti-CD20 monoclonal antibody within 6 months prior to randomization; other B-cell or plasma cell-depleting therapy within 6-12 months prior to randomization;
    3. Alkylating agent within 12 weeks prior to randomization;
    4. Any biologic for MG treatment within 12 weeks prior to randomization;
    5. Neonatal Fc receptor antagonist therapy within 8 weeks prior to randomization;
    6. Janus kinase (JAK), Bruton tyrosine kinase (BTK), or tyrosine kinase 2 (TYK2) inhibitor within 12 weeks prior to randomization;
    7. IVIg, subcutaneous immunoglobulin, or PLEX therapy within 4 weeks prior to randomization;
    8. Live/attenuated within 4 weeks prior to randomization, or planned vaccination during the study.
  3. A history of within 5 years prior to screening;
  4. Infection-related medical history and examinations:

    1. A history of herpes zoster meeting any of the following: 1) A history of disseminated herpes zoster, herpes zoster encephalitis, or ocular herpes zoster involving the retina; 2) Recurrent herpes zoster with 2 or more episodes within 2 years; 3) Herpes zoster infection not fully resolved within 12 weeks prior to screening;
    2. A history of tuberculosis (TB) or latent TB infection;
    3. A known history of primary immunodeficiency, splenectomy, or any underlying condition predisposing to infection;
    4. A history of recurrent infections requiring hospitalization and intravenous antibiotics;
    5. Any infection requiring hospitalization and/or intravenous antimicrobial therapy within 8 weeks prior to randomization, or any infection requiring oral antimicrobial therapy within 2 weeks prior to randomization;
    6. Positive test result for surface antigen (HBsAg), virus antibody, treponemal pallidum antibody, or (HIV) antibody; for patients with HBsAg-negative but hepatitis B core antibody (HBcAb)-positive, regardless of the status of hepatitis B surface antibody (HBsAb), HBV-DNA testing is required to confirm their condition, with HBV-DNA-positive patients excluded and HBV-DNA-negative patients eligible to participate in the study.
  5. General situation:

    1. Pregnant or lactating females;
    2. A history of alcohol abuse or illicit drug abuse within 1 year prior to screening;
    3. A history of allergic diathesis, or known /intolerance to any component of the product;
    4. Major surgery within 3 months prior to the screening, or planned major surgery during the study;
    5. Any condition that, in the investigator's judgment, may affect evaluation of study drug safety and efficacy, or any other condition that renders the subject ineligible.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Treatment group A: SHR-2173 injection

    Drug: SHR-2173 injection

  • Experimental
    Treatment group B: SHR-2173 injection

    Drug: SHR-2173 injection

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in MG-ADL total score

    Time frame: at Week 24

Secondary outcomes

  1. Change from baseline in Quantitative Myasthenia Gravis (QMG) score

    Time frame: at Week 24

  2. Change from baseline in Myasthenia Gravis Composite (MGC) total score

    Time frame: at Week 24

  3. Change from baseline in MG-ADL domain scores (ocular, bulbar, respiratory, limb)

    Time frame: at Week 24

  4. Change from baseline in QMG domain scores (ocular, bulbar, respiratory, limb)

    Time frame: at Week 24

  5. Proportion of participants with ≥3-point reduction from baseline in MG-ADL total score

    Time frame: at Week 24

  6. Proportion of participants with ≥50% reduction from baseline in MG-ADL total score

    Time frame: at Week 24

  7. Proportion of participants with ≥5-point reduction from baseline in QMG score

    Time frame: at Week 24

  8. Proportion of participants achieving Minimal Symptom Expression (MSE; MG-ADL total score 0 or 1) at Week 24

    Time frame: at Week 24

  9. Change from baseline in Myasthenia Gravis Quality of Life 15-item revised (MG-QoL15r) total score

    Time frame: at Week 24

  10. Change from baseline in Neuro-QoL Fatigue subscale score

    Time frame: at Week 24

  11. Change from baseline in European Quality of Life 5-Dimensions 5-Levels (EQ-5D-5L) index score

    Time frame: at Week 24

  12. Proportion of participants without rescue therapy

    Time frame: through Week 24

  13. Incidence, severity grading, and drug-relatedness of adverse events (AEs)

    Time frame: through Week 24

  14. Incidence, severity grading, and drug-relatedness of serious adverse events (SAEs)

    Time frame: through Week 24

  15. Incidence, severity grading, and drug-relatedness of adverse events of special interest (AESIs)

    Time frame: through Week 24

  16. Change from baseline in C-SSRS

    Time frame: through Week 24

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2027, 13 months after the start.

Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's planned 13 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 3, 2026
StartActual
Aug 28, 2026was Jun 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Xiangya Hospital of Central South University · Changsha, Chinano status→Recruiting
  • Huashan Hospital, Fudan University · Shanghai, Chinano status→Recruiting
Oct 22, 2026
Start date
Jun 2026→Aug 28, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Xiangya Hospital of Central South University · Changsha, Chinano status→Recruiting
    • Huashan Hospital, Fudan University · Shanghai, Chinano status→Recruiting
    Start date Jun 2026→Aug 28, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07622342
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Aug 28, 2026
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Kunming Li
Contact
kunming.li@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-2173

Start the discussion